A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Registration Number
- NCT01368445
- Lead Sponsor
- Meda Pharmaceuticals
- Brief Summary
The Purpose of this study is to evaluate the safety and efficacy of MP03-36 (0.15% azelastine hydrochloride)at dosages of 2 sprays per nostril once daily and 2 sprays per nostril twice daily in patients with seasonal allergic rhinitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 617
- Male and female patients 12 years of age and older
- Provide written informed consent/pediatric assent. If the patient is a minor, a parent or legal guardian must give written informed consent
- Screening Visit: Have a 12-hour reflective total nasal symptoms score ( TNSS) of at least 8 out of a possible 12 and a congestion score of 2 or 3 on Day -7
- Randomization Visit: Have a 12-hour reflective total nasal symptoms score (TNSS) (AM or PM) of at least 8 on 3 separate assessments (one of which was within 2 days of Day 1, and can include the morning of Day 1) during the Lead-in Period. In addition, an AM or PM nasal congestion score of 2 or 3 must have been recorded on 3 separate assessments (one of which was within 2 days of Day 1, and can include the morning of Day 1).
- Must have taken at least 10 doses of study medication during the lead-in period
- Randomization Visit: An instantaneous (TNSS) of ≥ 8 before beginning the onset of action assessment on Day 1
- Willing and able to comply with the study requirements
- At least a 2-year history of seasonal allergic rhinitis (SAR) during the fall pollen allergy season
- The presence of IgE-mediated hypersensitivity to local fall pollen confirmed by a positive response to either skin prick or intradermal testing within the last year. A positive response is defined as a wheal diameter of at least 3 mm larger than the control for the skin prick test or at least 7 mm larger than the control for the intradermal test.
- General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results as determined by the investigator or the sponsor's medical officer
- Patients receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit (adjustments to regimen following a brief period of missed injections does not preclude participation). Patients who are on maintenance doses of sublingual immunotherapy may be considered for the trial on a case-by-case basis after discussion with the sponsor's medical monitor or designee.
- The use of any investigational drug within 30 days prior to Day -7. No investigational products are permitted for use during the conduct of this study
- Presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol or sucralose (Splenda® brand sweetener)
- Women who are pregnant or nursing
- Women of childbearing potential who are not abstinent and not practicing a medically acceptable method of contraception
- Respiratory tract infections within two weeks prior to Day -7
- Respiratory Infections requiring oral antibiotic treatment two weeks prior to Day -7
- Other nasal disease(s) likely to affect deposition of intranasal medication, such as sinusitis, rhinitis medicamentosa or clinically significant polyposis or nasal structural abnormalities
- Patients with asthma (with the exception of mild, intermittent asthma)
- Patients with significant pulmonary disease
- Patients with a known history of alcohol or drug abuse
- Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug
- Clinically relevant abnormal physical findings within 1 week of randomization which, in the opinion of the investigator, would interfere with the objectives of the study or that may preclude compliance with the study procedures
- Planned travel outside the study area during the study period
- Family members and employees should be excluded
- Patients who received prohibited medications within specified timepoints in the protocol.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Arm && Interventions
Group Intervention Description Placebo Nasal Sapray azelastine hydrochloride 0.15% Nasal Spray 0mg, 2 sprays per nostril twice daily AM \& PM) MP03-36 Nasal Spray azelastine hydrochloride 0.15% Nasal Spray azelastine hydrochloride 0.15% MP03-36 and Placebo Nasal Spray azelastine hydrochloride 0.15% and Placebo azelastine hydrochloride 0.15% and Placebo Azelastine 0.1%, Nasal Spray Azelastine 0.1%, Nasal Spray Azelastine 0.1%, Nasal Spray Placebo Nasal Sapray azelastine hydrochloride 0.15% and Placebo 0mg, 2 sprays per nostril twice daily AM \& PM) Placebo Nasal Sapray Azelastine 0.1%, Nasal Spray 0mg, 2 sprays per nostril twice daily AM \& PM)
- Primary Outcome Measures
Name Time Method Change from baseline in 12-hour reflective total nasal symptoms score(TNSS) for the entire 14-day study period compared to placebo 14 Days
- Secondary Outcome Measures
Name Time Method Change from baseline in instantaneous total nasal symptoms score (TNSS) for the entire 14-day study period compared to placebo 14 Days Change from baseline to Day 14 in Roland Quality of Life Questionnaire (RQLQ )compared to placebo 14 Days Change From Baseline on Direct Visual Nasal Exams 14 Days
Trial Locations
- Locations (30)
AARA Research Center
🇺🇸Dallas, Texas, United States
Allergy Medical Group
🇺🇸Roseville, California, United States
Valley Clinical Research Center
🇺🇸Easton, Pennsylvania, United States
Atlantic Allergy, Asthma & Immunology
🇺🇸Ocean, New Jersey, United States
Northeast Medical Research Associates, Inc.
🇺🇸N. Dartmouth, Massachusetts, United States
West Coast Clinical Trials
🇺🇸Long Beach, California, United States
Allergy Research Foundation
🇺🇸Los Angeles, California, United States
Clinical Research Institute
🇺🇸Minneapolis, Minnesota, United States
North Carolina Clinical Research
🇺🇸Raleigh, North Carolina, United States
Coastal Allergy and Asthma P.C.
🇺🇸Savannah, Georgia, United States
Institute for Asthma and Allergy, P.C.
🇺🇸Wheaton, Maryland, United States
The Asthma and Allergy Center, PC
🇺🇸Papillion, Nebraska, United States
Princeton Center for Clinical Research
🇺🇸Skillman, New Jersey, United States
Sylvana Research Associates
🇺🇸San Antonio, Texas, United States
Allergy and Asthma Center
🇺🇸Waco, Texas, United States
Allergy and Clinical Immunology Associates
🇺🇸Pittsburgh, Pennsylvania, United States
Kansas City Allergy and Asthma
🇺🇸Overland Park, Kansas, United States
Research Across America
🇺🇸Dallas,, Texas, United States
AABI Associates Medical Group
🇺🇸Fountain Valley, California, United States
Southern California Research
🇺🇸Mission Viejo, California, United States
Allergy and Asthma Associates of CA
🇺🇸San Jose, California, United States
Allergy Associates Medical Group
🇺🇸San Diego, California, United States
The William Storms Allergy Clinic
🇺🇸Colorado Springs, Colorado, United States
Colorado Allergy and Asthma Centers, PC
🇺🇸Denver, Colorado, United States
Central Texas Health Research
🇺🇸New Braunfels, Texas, United States
Allergy and Asthma Consultants of NJ-PA, P.C
🇺🇸Collegeville, Pennsylvania, United States
Clinical Research Center
🇺🇸Cincinnati, Ohio, United States
Oklahoma Institute of Allergy and Asthma
🇺🇸Edmond, Oklahoma, United States
Allergy and Asthma Institue of Rochester
🇺🇸Rochester, New York, United States
Allergy Asthma Associates Research Dept.
🇺🇸Austin, Texas, United States